GO:0098911 regulation of ventricular cardiac muscle cell action potential: Electrophysiology, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098911 describes any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a ventricular cardiac muscle cell, typically via voltage-gated ion channels.
• The ventricular action potential is shaped by a coordinated flux of Na+, Ca2+, and K+ currents, and its regulation is essential for normal excitation-contraction coupling.
• Key molecular players include SCN5A (Nav1.5), CACNA1C (Cav1.2), potassium channels such as KCNQ1 and KCND3, and accessory proteins like FGF13 and NCX1.
• Disruption of this regulation causes arrhythmias, including long QT syndrome, Brugada syndrome, and heart failure-associated electrical remodeling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate genes in this process.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to dissect the genetic regulation of ventricular action potentials.
Description
The ventricular cardiac muscle cell action potential is the electrical signal that triggers each heartbeat, and its precise regulation is required for synchronous contraction of the ventricles. GO:0098911, regulation of ventricular cardiac muscle cell action potential, captures the biological processes that modulate the frequency, rate, or extent of action potential creation, propagation, or termination in these cells, typically through changes in voltage-gated ion channel activity or expression. This term is central to cardiac electrophysiology because even small shifts in ion channel function can predispose to lethal arrhythmias. Researchers studying GO:0098911 aim to understand how ion channels, transporters, and accessory proteins interact to shape the action potential waveform and how their dysfunction leads to disease. The term is also critical for interpreting data from genome-wide association studies, drug safety assays, and CRISPR screens that perturb cardiac electrical function.
regulation of ventricular cardiac muscle cell action potential At A Glance
| GO ID | GO:0098911 |
|---|---|
| GO term | regulation of ventricular cardiac muscle cell action potential |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate, or extent of action potential creation, propagation, or termination in ventricular cardiac muscle cells, typically via voltage-gated ion channels |
| Related cellular components | Sarcolemma, T-tubules, intercalated discs, and ion channel complexes |
| Key ion currents | INa, ICa-L, Ito, IKs, IKr, IK1 |
| Associated diseases | Long QT syndrome, Brugada syndrome, arrhythmogenic cardiomyopathy, heart failure |
| Research methods | Patch clamp, optical mapping, CRISPR screens, transcriptomics, proteomics |
What Is GO:0098911?
GO:0098911 is a biological process term defined as any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a ventricular cardiac muscle cell contributing to the regulation of its contraction, typically occurring via modulation of the activity or expression of voltage-gated ion channels.
Why Is regulation of ventricular cardiac muscle cell action potential Important in Cell Biology?
GO:0098911 is important because the ventricular action potential is the final common pathway for cardiac electrical excitability, and its dysregulation directly causes arrhythmias and sudden cardiac death. Understanding this process at molecular resolution is essential for drug development, safety pharmacology, and precision medicine in cardiology.
• Defines the electrical behavior of ventricular myocytes that underlies every heartbeat.
• Dysregulation causes inherited and acquired arrhythmias, including long QT syndrome and Brugada syndrome.
• Ion channel trafficking and accessory proteins are emerging regulators of action potential duration.
• Provides a mechanistic framework for interpreting genetic variants in cardiac ion channel genes.
• Critical for cardiac safety pharmacology of non-cardiac drugs that block hERG or other channels.
• Enables CRISPR-based functional genomics of cardiac excitability.
• Links metabolic state, such as intracellular ATP, to electrical activity.
• Informs development of gene therapies and cell models for arrhythmia research.
What Happens During regulation of ventricular cardiac muscle cell action potential?
Phase 0: Rapid Depolarization
In simple terms: The cell rapidly becomes positive inside due to sodium entry.
In ventricular myocytes, phase 0 depolarization is driven by a large, fast inward sodium current (INa) through voltage-gated sodium channels, primarily Nav1.5 encoded by SCN5A. Regulation of this phase involves modulation of channel availability, trafficking, and post-translational modifications; for example, USP10-mediated de-ubiquitination and chaperone-mediated autophagy can degrade cardiac sodium channels and alter excitability. The cholinergic system also modulates electrical conduction in the heart, influencing the initial depolarization.
Phase 1 and 2: Early Repolarization and Plateau
In simple terms: The cell briefly repolarizes then holds a plateau as calcium enters and potassium leaves.
Phase 1 is mediated by transient outward potassium current (Ito), while the phase 2 plateau results from a balance between L-type calcium current (ICa-L) through Cav1.2 (CACNA1C) and repolarizing potassium currents. Regulation of Cav1.2 trafficking and surface expression is a key determinant of plateau duration and excitation-contraction coupling. Intracellular ATP dynamics also modulate these currents during excitation-contraction coupling.
Phase 3: Repolarization
In simple terms: Potassium exits the cell to bring the voltage back down.
Phase 3 repolarization is driven by multiple potassium currents, including IKs (KCNQ1/KCNE1), IKr (hERG/KCNH2), and IK1 (KCNJ2). The pharmacology and regulation of these channels are well characterized, and their modulation by drugs or genetic variants can prolong or shorten action potential duration, increasing arrhythmia risk. FGF13 has been shown to regulate cardiomyocyte impulse propagation via connexin-43 trafficking, indirectly affecting repolarization timing.
Phase 4: Resting Potential and Pacemaking
In simple terms: The cell returns to its resting voltage and is ready for the next beat.
The resting membrane potential is maintained by IK1 and the sodium-calcium exchanger NCX1, which is regulated by sodium-dependent inhibition. NCX1 activity influences intracellular calcium and electrical stability, and its dysregulation contributes to arrhythmogenesis. Rate dependence of the action potential and calcium transient is a hallmark of ventricular myocytes, as shown in canine cardiac ventricular cell models.
Integration and Propagation
In simple terms: The electrical signal spreads from cell to cell through gap junctions.
Action potential propagation in ventricular tissue depends on gap junctions, particularly connexin-43, whose trafficking is regulated by FGF13 in a VGSC-independent manner. This ensures coordinated contraction of the ventricular syncytium. Disruption of propagation can lead to conduction block and reentrant arrhythmias.
Key Genes Involved in GO:0098911 regulation of ventricular cardiac muscle cell action potential
The following genes encode ion channels, transporters, and accessory proteins that directly regulate the ventricular cardiac muscle cell action potential.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCN5A | Encodes Nav1.5, the main cardiac sodium channel mediating phase 0 depolarization | Mutations cause Brugada syndrome and long QT syndrome; target for CRISPR knockout and point mutation studies |
| CACNA1C | Encodes Cav1.2, the L-type calcium channel underlying the plateau phase | Mutations cause Timothy syndrome; key for trafficking and electrophysiology studies |
| KCNH2 | Encodes hERG, the rapid delayed rectifier potassium channel (IKr) | Drug-induced long QT syndrome; essential for safety pharmacology |
| KCNQ1 | Encodes Kv7.1, the slow delayed rectifier potassium channel (IKs) | Mutations cause long QT syndrome type 1; target for functional studies |
| KCNJ2 | Encodes Kir2.1, the inward rectifier potassium channel (IK1) | Mutations cause Andersen-Tawil syndrome; regulates resting potential |
| KCND3 | Encodes Kv4.3, contributing to transient outward current (Ito) | Mutations linked to Brugada syndrome and early repolarization |
| NCX1 (SLC8A1) | Sodium-calcium exchanger regulating calcium and electrical stability | Sodium-dependent inhibition modulates action potential; target for knock-in studies |
| FGF13 | Fibroblast growth factor 13 regulating connexin-43 trafficking and impulse propagation | VGSC-independent regulator; knockout models show conduction defects |
| USP10 | De-ubiquitinase controlling cardiac sodium channel stability | Knockout causes sodium channel degradation and arrhythmias |
| CHAT | Choline acetyltransferase in endogenous cholinergic system controlling conduction | Modulates electrical conduction; target for optogenetic and knockout studies |
| ATP-sensitive K+ channels (KCNJ11/ABCC9) | Link metabolic state to action potential duration | Relevant for ischemic arrhythmias; CRISPR models available |
| Cx43 (GJA1) | Gap junction protein mediating electrical coupling | FGF13-dependent trafficking; knockout impairs propagation |
| SCN1B | Beta subunit modulating Nav1.5 gating and trafficking | Mutations cause Brugada syndrome; co-expression studies |
| CALM1 | Calmodulin regulating Cav1.2 and other channels | Mutations cause long QT syndrome; CRISPR point mutation models |
| ANK2 | Ankyrin-B anchoring ion channels and transporters | Mutations cause long QT syndrome type 4; trafficking studies |
| KCNE1 | Beta subunit modulating KCNQ1 (IKs) | Mutations cause long QT syndrome; knock-in models |
| HCN4 | Pacemaker channel contributing to diastolic depolarization | Relevant for spontaneous activity; overexpression models |
| RYR2 | Ryanodine receptor mediating calcium release from sarcoplasmic reticulum | Mutations cause CPVT; calcium imaging studies |
How Is regulation of ventricular cardiac muscle cell action potential Regulated?
The regulation of ventricular cardiac muscle cell action potential is itself modulated by multiple signaling pathways and cellular processes. Intracellular ATP dynamics directly influence ion channel activity and excitation-contraction coupling, linking metabolic state to electrical function. The endogenous cholinergic system controls electrical conduction in the heart, providing autonomic regulation of action potential initiation and propagation. Protein quality control pathways, such as USP10-mediated de-ubiquitination and chaperone-mediated autophagy, regulate the stability of cardiac sodium channels and thus excitability. Additionally, FGF13 regulates gap junction trafficking independently of voltage-gated sodium channels, affecting impulse propagation. These layers of regulation ensure that the action potential adapts to physiological demands but also create vulnerabilities for arrhythmias when disrupted.
regulation of ventricular cardiac muscle cell action potential and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SCN5A | Brugada syndrome, long QT syndrome type 3 | CRISPR knockout or point mutation in iPSC-derived cardiomyocytes |
| KCNH2 | Long QT syndrome type 2, drug-induced arrhythmia | Knockout and overexpression models for drug testing |
| KCNQ1 | Long QT syndrome type 1 | Knock-in of patient mutations in cell lines |
| NCX1 (SLC8A1) | Heart failure, calcium overload arrhythmias | Knock-in of sodium-binding mutations |
| FGF13 | Conduction defects, arrhythmogenesis | Knockout and tagged knock-in for trafficking studies |
Inherited Arrhythmia Syndromes
Mutations in genes encoding cardiac ion channels cause inherited arrhythmia syndromes such as long QT syndrome and Brugada syndrome. For example, loss-of-function mutations in SCN5A lead to Brugada syndrome, while gain-of-function mutations cause long QT syndrome type 3. Dysregulation of sodium channel stability by USP10 can also cause cardiac arrhythmias. These conditions highlight the critical role of GO:0098911 in maintaining normal cardiac rhythm.
Heart Failure and Electrical Remodeling
In heart failure, ventricular action potential duration is often prolonged due to downregulation of potassium currents and altered calcium handling. NCX1 dysregulation contributes to calcium overload and arrhythmogenesis. Understanding these remodeling processes is essential for developing therapies that target GO:0098911.
Drug-Induced Arrhythmias
Many drugs block hERG (KCNH2) or other potassium channels, prolonging the action potential and causing acquired long QT syndrome. This makes GO:0098911 a key term in cardiac safety pharmacology, where CRISPR models can be used to test drug effects on specific ion channels.
From regulation of ventricular cardiac muscle cell action potential-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SCN5A affect action potential upstroke? | CRISPR knockout in iPSC-derived cardiomyocytes |
| Does a specific point mutation in KCNH2 alter IKr? | Point mutation knock-in in HEK293 or cardiomyocytes |
| How does NCX1 sodium sensitivity regulate action potential? | Knock-in of mutant NCX1 in mouse or cell lines |
| Where does FGF13 localize during Cx43 trafficking? | Tagged knock-in of FGF13 with fluorescent tag |
| Does overexpression of CACNA1C prolong plateau? | Overexpression in ventricular myocytes |
| What genes regulate action potential duration? | CRISPR library screening in cardiomyocytes |
How to Study the regulation of ventricular cardiac muscle cell action potential Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch clamp | Ionic currents and action potential waveform | Functional validation of ion channel mutations |
| Optical mapping | Action potential propagation and calcium transients | Conduction velocity and arrhythmia studies |
| RNA-seq | Gene expression changes | Identifying ion channel remodeling |
| Proteomics | Protein abundance and modifications | Sodium channel degradation studies |
| CRISPR screen | Gene function at scale | Discovery of novel regulators |
| Calcium imaging | Intracellular calcium dynamics | Excitation-contraction coupling studies |
| Immunofluorescence | Protein localization and trafficking | Channel trafficking studies |
| Western blot | Protein expression and ubiquitination | USP10-mediated degradation assays |
Patch Clamp Electrophysiology
Patch clamp recording measures ionic currents and action potentials directly in ventricular myocytes, allowing precise quantification of the effects of genetic perturbations on GO:0098911. This method is the gold standard for assessing ion channel function and drug responses.
Optical Mapping and Calcium Imaging
Optical mapping using voltage- and calcium-sensitive dyes enables simultaneous measurement of action potential propagation and calcium transients in multicellular preparations. This is particularly useful for studying conduction and arrhythmia mechanisms.
Transcriptomics and Proteomics
RNA sequencing and proteomics can identify changes in ion channel expression and post-translational modifications that regulate the action potential. These approaches are often combined with CRISPR perturbations to uncover regulatory networks.
CRISPR Screening
Pooled CRISPR screens with electrophysiological or survival readouts can identify novel regulators of ventricular action potential. This unbiased approach is powerful for discovering genes that modulate excitability.
How CRISPR Can Be Used to Study GO:0098911 regulation of ventricular cardiac muscle cell action potential
Knockout
CRISPR knockout of genes such as SCN5A, KCNH2, or FGF13 in cardiomyocytes can reveal their essential roles in the ventricular action potential. Knockout models are used to assess loss-of-function effects on action potential duration and arrhythmia susceptibility.
Point Mutation
Introducing patient-specific point mutations (e.g., in KCNQ1 or SCN5A) via CRISPR allows precise modeling of inherited arrhythmia syndromes and testing of genotype-specific drug responses.
Knock-in
Knock-in of reporter tags or disease alleles (e.g., NCX1 sodium-binding mutants) enables real-time tracking of channel trafficking and function in the context of GO:0098911.
Overexpression
Overexpression of CACNA1C or other ion channels can mimic gain-of-function states and help dissect the contribution of individual currents to the action potential plateau.
How EDITGENE Supports regulation of ventricular cardiac muscle cell action potential Research
Researchers studying regulation of ventricular cardiac muscle cell action potential-related genes often need to determine whether a candidate gene is causally involved in electrical excitability or simply correlated with it. EDITGENE provides the CRISPR tools and cell models to establish causality.
Contact EDITGENE today to design your custom CRISPR model for regulation of ventricular cardiac muscle cell action potential research.
Frequently Asked Questions About regulation of ventricular cardiac muscle cell action potential
What is GO:0098911?
GO:0098911 is the Gene Ontology term for regulation of ventricular cardiac muscle cell action potential, defined as any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a ventricular cardiac muscle cell, typically via voltage-gated ion channels.
What genes are involved in regulation of ventricular cardiac muscle cell action potential?
Key genes include SCN5A, CACNA1C, KCNH2, KCNQ1, KCNJ2, KCND3, NCX1, FGF13, USP10, and GJA1, among others.
How is the ventricular action potential regulated?
It is regulated by the activity and expression of voltage-gated ion channels, accessory proteins, gap junctions, and signaling pathways such as the cholinergic system and protein quality control.
What diseases are associated with dysregulation of ventricular action potential?
Dysregulation causes long QT syndrome, Brugada syndrome, heart failure-associated arrhythmias, and drug-induced arrhythmias.
What methods are used to study GO:0098911?
Patch clamp, optical mapping, calcium imaging, RNA-seq, proteomics, and CRISPR screens are commonly used.
Can CRISPR be used to study ventricular action potential regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to test gene function in cardiac electrophysiology.
What is the role of SCN5A in the ventricular action potential?
SCN5A encodes Nav1.5, the main sodium channel responsible for phase 0 depolarization; its regulation is critical for normal excitability.
How does FGF13 regulate cardiac conduction?
FGF13 regulates cardiomyocyte impulse propagation via connexin-43 trafficking, independent of voltage-gated sodium channels.
What is the role of NCX1 in action potential regulation?
NCX1 is a sodium-calcium exchanger whose sodium-dependent inhibition modulates calcium and electrical stability.
Why is intracellular ATP important for the ventricular action potential?
Intracellular ATP dynamics during excitation-contraction coupling can influence ion channel activity and action potential duration.
Conclusion
GO:0098911, regulation of ventricular cardiac muscle cell action potential, is a fundamental biological process that integrates ion channel function, accessory protein regulation, and metabolic state to ensure normal cardiac rhythm. Its dysregulation underlies a spectrum of arrhythmic diseases, making it a prime target for mechanistic and therapeutic research. CRISPR-based models and advanced electrophysiological methods now enable precise dissection of this process, and EDITGENE offers comprehensive services to accelerate discovery in this field.
References
- 1. Xie D et al.. 2025. An endogenous cholinergic system controls electrical conduction in the heart.. Eur Heart J 46(13):1232-1246 PMID: 39437249
- 2. Xiong H et al.. 2025. Coupling of USP10 de-ubiquitination and chaperone-mediated autophagy causes cardiac sodium channel degradation and cardiac arrhythmias.. Cardiovasc Res 121(16):2520-2533 PMID: 41213870
- 3. Rhana P et al.. 2024. Fueling the heartbeat: Dynamic regulation of intracellular ATP during excitation-contraction coupling in ventricular myocytes.. Proc Natl Acad Sci U S A 121(25):e2318535121 PMID: 38865270
- 4. Westhoff M et al.. 2021. Mechanisms and Regulation of Cardiac Ca(V)1.2 Trafficking.. Int J Mol Sci 22(11) PMID: 34072954
- 5. Scranton K et al.. 2024. Cardiac function is regulated by the sodium-dependent inhibition of the sodium-calcium exchanger NCX1.. Nat Commun 15(1):3831 PMID: 38714663
- 6. Hund TJ et al.. 2004. Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model.. Circulation 110(20):3168-74 PMID: 15505083
- 7. Das LT et al.. 2025. FGF13 Regulates VGSC-Independent Cardiomyocyte Impulse Propagation via Cx43 Trafficking.. Circ Res 137(12):1522-1539 PMID: 41200819
- 8. Li GR et al.. 2010. Pharmacology of cardiac potassium channels.. Adv Pharmacol 59:93-134 PMID: 20933200
